BreakThrough Digest - cancer,  medical information

BreakThrough Digest offers current medical news and health articles on medical breakthroughs, medical research and health information on clinical trials, cancer, Alzheimer's, stem-cell research, heart disease, diabetes and more.



HOME

RECENT HEADLINES

NEW RESEARCH

CLINICIAL TRIALS

COMMENTARY

FDA NEWS DIGEST

ADVERTISE

RESOURCES

Quick Links to:

  - Medical Journals
  - Government Health Sites
  - Pharmaceutical Companies
  - Archives
  - A Challenge for Health IT
  - Mobile Edition

Advertisers...

Neprinol
- exclusive distributors of pharmaceutical-grade products including neprinol, syntol, and devacor

Chelation - cardio renew is 100% pure edta providing cardiovascular cleansing by oral chelation.

 Bladder Cancer & Research in the News

Diagnosed With
DALLAS, Feb. 2, 2012 /PRNewswire/ --  Originally prescribed by physicians across America for the treatment of type 2 diabetes, the prescription drug Actos (pioglitazone) was pulled from the market in June 2011 when the US Food and Drug ...

Long-Term Benefits With Chemoradiation for
February 6, 2012 (San Francisco, California) — In muscle-invasive

Actos Lawsuits Allege Link to
A number of Actos lawsuits have been filed against drug maker Takeda Pharmaceutical Co., alleging that its diabetes drug causes

Actos Lawsuit Attorneys Continue to Investigate
As the number of Actos lawsuits begins to climb, the attorneys at Morgan and Morgan continue to investigate claims on behalf of users of the diabetes drug who were diagnosed with

Arsenic
NEW YORK (Reuters Health) - People exposed to very high levels of arsenic in Chilean drinking water back in the 1950s and 60s are still showing a higher-than-normal risk of

Dogs Get
a

Lawsuit Over
A California man has won a battle to keep his Actos lawsuit over

IMPORTANT: Bing News RSS feed has moved!
Go to the new RSS page and renew your subscription.


Metal-on-Metal Hip Implant Study Reportedly Raises
According to a report from The Telegraph, the British study reportedly found that one in five patients fitted with an all-metal hip implant experienced changes to cells in the

Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary
BOTHELL, Wash. and VANCOUVER , British Columbia, Feb. 2, 2012 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI - News) announced today preliminary results from an investigator-sponsored Phase 1 study of patients with superficial

 

Google

BreakThrough Digest
Copyright 2007 BreakThrough Digest
BreakThrough Digest subscribes to the eHealth Code of Ethics

 

medical new and medical breakthroughs health information and health articles about medicine on cancer, heart disease, diabetes and stem cell research

medrocket award

Trute